- Home
- Reducing Cardiovascular Risk With Effective Management Of LDL Cholesterol - A Roundtable Discussion
Reducing Cardiovascular Risk With Effective Management Of LDL Cholesterol - A Roundtable Discussion
Topic:
- Prevention
Available Credit:
- Not accredited
Course Published On:
Course Expiry Date:
Overview
This roundtable is designed to provide clinicians with a better understanding of the long-term CV risks of LDL-C exposure. In addition to reviewing the pathogenesis of atherosclerosis and assessing the long-term implications of elevated LDL-C, this meeting will consider current guidance around controlling LDL-C, the challenges in achieving LDL-C targets, and evaluating how emerging strategies are contributing to LDL-C management.
Each chapter will comprise of a short presentation by the named medical expert followed by a panel discussion amongst all faculty.
Target Audience
- Healthcare Professionals
- General Cardiologists
Learning Objectives
Upon completion of this activity, participants will be able to:
- Outline the pathogenic nature and clinical risk of extended exposure to elevated LDL-C
- Describe the clinical challenges in achieving guidance-based LDL-C goals
- Compare and contrast LDL-C lowering therapies
This course is not accredited
Related Courses
Revolutionising Thrombosis Treatment in ACS, SSP and AF
- 1.00
Published:
Learning objectives
- Discuss the unmet needs in thrombosis management, MACE burden after ACS, stroke in AF and secondary stroke prevalence and consequences
- Evaluate the current standard of care for the treatment of ACS, SSP and AF and its limitations
- Review guidelines and critique current prescribing practices and the implications of inadequate treatment
- Explain the different strategies for targeting FXI and how FXI inhibition mechanisms differentiate from traditional anticoagulation therapies
- Identify emerging anticoagulant strategies and describe the efficacy and safety data from Phase 2 FXI inhibitor clinical trials as well as ongoing Phase 3 trials and potential place in therapy for ACS, AF and SSP
- Apply evidence-based anticoagulation strategies by optimising treatment decisions and addressing patient-specific risk factors
The Rise of CVRM Medicine: Managing Common Co-morbidities as One
- 3.00
Published:
Learning objectives
- Describe the link between T2DM, CKD and ASCVD
- State the importance of early and effective intervention in managing CVRM disease progression
- List the guideline directed therapeutic targets in CVRM disease
- Select appropriate patients for holistic CVRM management
- Recall trial data for novel therapeutic agents that carry benefit for CVRM outcomes
- Develop a holistic management strategy for CVRM disease with an evidence-based impact on clinical outcomes
Managing Hypertension in CVD: How Low Can We Go?
- 1.00
Published:
Learning objectives
- Describe the link between CVD and hypertension
- Classify hypertension patients according to their cardiovascular risk
- Recall recent guideline-directed and evidence-based strategies for managing very high CVD risk patients
- Apply guideline-directed and evidence-based management strategies to a case study
- Use expert guidance to adopt optimal multidisciplinary antihypertensive management strategies in patients with very high cardiovascular risk
Advancements in Triglyceride-lowering Therapies
- 1.00
Published:
Learning objectives
- Recall the primary and secondary outcomes from key triglyceride-lowering trials presented during ESC 2024
- Discuss the current and future implication of trial results to clinical management and practice guidelines
Elevating Understanding and Management of Hypertriglyceridemia
- 1.25
Published:
Learning objectives
- Understand HTG as a risk factor for acute and chronic illness
- Describe current guideline directed management of HTG
- Recognise the gaps and challenges present in current guideline directed management of HTG
- Recall emerging trial data for novel pharmacological targets
- Use guidelines, trial data & expert opinion to develop individualised treatment strategies for high-risk patients